AngioDynamics (ANGO) Misses Q1 EPS by 4c, Reaffirms FY18 Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq fall as megacap tech drags; Iran developments watched
- Oil falls 4% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- China makes small dent in deflation battle as supply-demand imbalance persists
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
AngioDynamics Reports Fiscal 2018 First Quarter Results
September 28, 2017 6:00 AM EDTQ1 net sales of $85.4 million, down 3% year-over-year       Q1 GAAP earnings per share of $0.00; adjusted EPS of $0.12Q1 operating cash generation of $3.0 million; free cash flow generation of $2.5 millionCompany reaffirms fiscal 2018 guidance
ALBANY, N.Y., Sept. 28, 2017 (GLOBE NEWSWIRE) -- AngioDynamics (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, today reported first quarter financial results for the 2018 fiscal year ended August 31, 2017.
The first quarter of fiscal 2018 reflects early results of our commitment to improving our core operational efficiency and... More
